A Collaboration Between INRS and NMX Research and Solutions that Accelerates Drug Discovery

Although Fragment-Based Lead Discovery (FBLD) is one of the most promising strategies for discovering future medical compounds, there are still until today barriers that discourage industry from pursuing this approach.

NewsGuest UserNovember 9, 2022BIOOQuébecbiotechnology, NACFC, Laurent Pharmaceuticals, Cystic Fibrosis

Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing LAU-7b (oral fenretinide) as a first-in-class inflammation-controlling drug candidate for Cystic Fibrosis (CF), announces the presentation of results from its placebo-controlled Phase 2 APPLAUD 24-week clinical study in adults with CF at the North American Cystic Fibrosis Conference (NACFC) currently held in Philadelphia, United States.

NewsGuest UserNovember 8, 2022BIOOQuébecbiotechnology, NACFC, Laurent Pharmaceuticals, Cystic Fibrosis